Online inquiry

IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9885MR)

This product GTTS-WQ9885MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Cystic Fibrosis (CF) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9885MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9484MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ2949MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ13384MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ13453MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ7352MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ9071MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ5847MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ13376MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PR-1498487
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW